Other News

Implanted Cardiac Device: Newest Ransomware Target

by Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) It has the makings of a plot for a blockbuster movie: a high ranking government official or world leader assassinated by a nefarious hacker who remotely accesses an implanted cardiac device. Plot lines and prominent world leaders notwithstanding, cyber-security risks for implantable cardiac […]

Malin Announces U.S. FDA Approval for New Hourglass™ Peripheral Embolisation Plug

DUBLIN–(BUSINESS WIRE)–Malin Corporation plc. (ISE:MLC, “Malin”), an Irish based and globally operating life sciences company, today announced that its EMBA device, known as the Hourglass™ Peripheral Embolisation Plug, was granted U.S. FDA 510(k) clearance to commence marketing in the US. The Hourglass™ peripheral embolisation plug represents a breakthrough in peripheral […]

Getinge Announces Full U.S. Availability Of Pulsar-18 Self-Expanding Stent From BIOTRONIK For Patients With Peripheral Artery Disease

WAYNE, N.J., Aug. 22, 2017 /PRNewswire/ — Getinge, a leading global provider of innovative medical technology, today announces the full U.S. market release of the Pulsar®-18 stent from BIOTRONIK. Pulsar-18 is the only available self-expanding stent for blocked superficial femoral arteries with a 4-French (4F) delivery system. Getinge currently distributes BIOTRONIK’s portfolio of […]

InspireMD Shares CGuard EPS Video Testimonials From European Key Opinion Leaders

TEL AVIV, ISRAEL–(Marketwired – August 22, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (NYSE American: NSPR.WS) (NYSE MKT: NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has posted video testimonials about its CGuard™ Embolic Prevention System from […]

InspireMD Announces Notification Of NYSE AMERICAN Listing Deficiency And Expectation To Regain Compliance

TEL AVIV, ISRAEL–(Marketwired – August 22, 2017) – InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it received a letter from the NYSE American on August 17, 2017 indicating that InspireMD does not […]

BioVentrix Announces First Patient Enrolled In IDE Study Of The Revivent TC Transcatheter Ventricular Enhancement Treatment For Ischemic Cardiomyopathy

SAN RAMON, Calif. and CAMBRIDGE, England, Aug. 21, 2017 /PRNewswire/ — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the international arm of the ALIVE pivotal clinical trial. The trial is designed to demonstrate the safety and effectiveness of […]

Cardiome Provides U.S. Regulatory Update For BRINAVESS

VANCOUVER, Aug. 21, 2017 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME/ TSX:COM) today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory path for BRINAVESS® (vernakalant hydrochloride, IV), the Company’s antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF).  In its […]

BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker

LAKE OSWEGO, Ore., Aug. 21, 2017 /PRNewswire/ — BIOTRONIK today announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI AutoDetect technology. With a volume of 15 cc, Edora HF-T QP is the smallest MR conditional CRT-P available in the US with […]

Self Healing Heart cells May Regenerate Repair of Damaged Hearts

Repairing damaged hearts with self-healing heart cells PUBLIC RELEASE: 21-AUG-2017, NATIONAL UNIVERSITY HEALTH SYSTEM Singapore – New research has discovered a potential means to trigger damaged heart cells to self-heal. The discovery could lead to groundbreaking forms of treatment for heart diseases. For the first time, researchers have identified a long non-coding […]

Endologix Announces Positive Clinical Results From The LEOPARD Clinical Study

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced positive interim results from the LEOPARD (Looking at Evar Outcomes by Primary Analysis of Randomized Data) clinical study. LEOPARD is the first and only head-to-head, prospective, multi-center, randomized clinical study comparing currently available endovascular abdominal aortic stent grafts. LEOPARD […]